JUNE 2016


This year, the 18th Nutrition Meetings of Institut Pasteur de Lille will be helpful !

The first day, 9 June, will provide an opportunity to optimise your cerebral functions on the topic of "Brain and nutrition »

The second day, 10 June, will be used to improve your pace of life on the topic of "Sleep, rhythms, diet and weight »

You know how important and topical these issues are. This year, more than ever, you need to attend the Nutrition Meetings of Institut Pasteur de Lille. You will not regret it.

See you soon.

Dr Jean Michel Lecerf

Go to the website

MAY 2016

patrick berche signature Inria

Framework agreement with Inria

On 3 May 2016, Patrick Berche, managing director of the Institut Pasteur de Lille, and Antoine Petit, chairman and managing director of Inria concluded a framework contract to establish closer cooperation between the teams of the Institute and Inria.

The Inria, national research institute dedicated to digital technology is a public establishment that employs 2700 employees, 360 of which spread across the 17 research teams of its centre in Villeneuve d’Ascq. Recognised for its strong dedication in the socio-economic development of the Hauts-de-France region, the Inria Lille - Nord Europe research centre, is committed to its work alongside its academic, institutional and industrial partners on major research and innovation projects in the digital domain. That's why Inria is signing a cooperation framework agreement with Institut Pasteur de Lille

The purpose of this agreement is to establish closer cooperation between the teams of the campus of Institut Pasteur and of the Inria with projects in the following areas, in particular:

  • research in bioinformatics, e.g. the development of tools for analysing genomes and large-scale sequencing. This research includes the definition of effective combinatorial and algorithmic models, implementing robust and distributed software and the approval of biological data.

  • research in machine learning: this involves developing effective procedures for extracting complex data using large volumes. This includes classification and forecasting issues. The learning process requires expertise that is at the dividing line between applied mathematics and IT.

  • research in integrative biology: the inclusion of clinical data, omics (genomics, transcriptomics, epigenomics, etc.) or imagery requires developments in IT in order to integrate the different databases as well as developments in applied mathematics (linked to the learning domain mentioned above or not) in order to define appropriate models.

Shared workshops will be used by the researchers of both institutes to understand new avenues of research and put together scientific road maps that are original and of the highest international standard.

These projects could be jointly supported by the institutions but they can also benefit from the cross-financing of the institute's longevity research centre and the "Advanced Data Science and Technologies" project (Data), both of which are financed as part of the 2015-2020 state-region plan framework agreement.

Third Chemical Ligation Meeting. 26th & 27th may, 2016

The third Chemical Ligation Meeting is a one-day international meeting focused on ligation chemistry broadly defined. The meeting will cover a large range of topics from synthetic methodology applied to peptides, proteins, polysaccharides or nucleic acids to applications in medicine and materials. Contributions in the field of bioconjugation, biorthogonal and in vivo chemistry, chemical protein synthesis or the design, synthesis and study of complex biomolecular assemblies are particularly welcome.

The official language of the meeting will be english.


Lire le flyer

Miniaturisation, Micro and Nanotechnologies: Ethical issues of emerging technologies -18 MAY 2016

Conference at Institut Pasteur de Lille on 18 May 2016.

The event aims to clarify and analyse a certain number of ethical concerns associated with the development of micro and nanotechnologies, particularly in the area of biology and health, where they are most evident.

Bringing together technology experts, doctors, practitioners, philosophers and the general public, the one-day conference also aims to unite a multidisciplinary community that is interested in the ethical aspects of developing new technologies and keen to debate them.

The one-day conference will be held at Institut Pasteur de Lille, (Buttiaux amphitheatre), 1 rue du Professeur Calmette in Lille. It is open to everyone. Online reservations are free and mandatory.



MARCH 2016

The Industry Prize of Institut Pasteur de Lille awarded to Dr Alain Baulard for his work on tuberculosis

On Thursday 17 March, Dr Alain Baulard, head of research at INSERM, was honoured for his work in putting together a new concept of medication against tuberculosis. If you would like to find out more, feel free to read the detailed explanation of Dr Baulard's research work!

Read the press release



Chemical biology of antibiotics: a new team is joining the CIIL

Resistance to antibiotics is a major public health problem that is constantly on the rise in the world. If new solutions are not found, it is estimated that 10 million people will die from an infection caused by a germ that is resistant to antibiotics by 2050. The cost associated with these infections will approach €100 billion.

Hospital-acquired infections, which are a direct consequence of this resistance, affect one patient in 20 hospitalised in France. What's more, an increasing number of cases of multi-resistance are being recorded for certain diseases, such as tuberculosis. 450,000 new cases were recorded in 2014 throughout the world.

This type of infection is extremely difficult to combat and it is crucial that new therapeutic molecules are discovered soon. That's why a research group
entitled "chemical biology of antibiotics" joined the CIIL to develop innovative approaches for identifying new antibiotics, defining their targets and improving the properties of these therapeutic molecules.

For a long time now, the research world has been aware of the capacity of bacteria and fungi to produce antibiotics. Medicines, such as penicillin or even antitubercular drugs such as rifampicin or streptomycin, come directly from the production of these microscopic beings.

"Not only are we aware that bacteria are capable of producing antibiotics, but we also know, thanks to recent genetic studies, that 90 to 95% of these capacities are disabled inside bacteria. My research is devoted to finding out how to activate this natural process and break down the barriers," explained Ruben Hartkoorn, the head of the new team.

At the age of 35, Ruben Hartkoorn has consequently put together his own research team at Institut Pasteur de Lille. A team funded by the ATIP-Avenir programme, the invitation to tender of the INSERM and the CNRS, which gives young researchers the opportunity to launch their own projects.

Recently appointed to take charge of research at the INSERM, this Dutch pharmacologist has just spent six years as part of Stewart Cole's team studying the microbiology of pathogens at the "Ecole Polytechnique Fédérale" of Lausanne. He is currently working with Eva Desmecht, a laboratory technician recruited by the Institute, and will recruit some post-doctoral researchers to supplement the team.

Scientifics News from Institut Pasteur de Lille (Original language)




Le rôle capital de la flore intestinale dans le succès d’une immunothérapie vient d’être dévoilé dans une étude parue dans la revue Science. Des bactéries intestinales capables d’améliorer la réponse thérapeutique de ce médicament et de diminuer un effet secondaire régulièrement rencontré avec ce traitement, une « colite inflammatoire», ont été identifiées. Lire la suite via le communiqué de presse.

Contact : Mathias CHAMAILLARD